ABSTRACT

Introduction: Recent studies place the risk of infection following inflatable penile prosthesis (IPP) implantation at 1–2%. This risk may be underestimated due to the exclusion of high-risk patients, such as patients undergoing multiple revisions or revision following IPP infection, from data.

Aim: To calculate the rate of postoperative complications for all patients undergoing IPP implantation and revision, and to determine the risk factors predictive of complications following virgin implantation and revision independently.

Methods: The charts of 280 patients undergoing 331 IPP implantations performed over the last 20 years at a large academic medical center were reviewed for postoperative complications and suspected preoperative and operative risk factors.

Main Outcome Measure: This included the prevalence of adverse operative outcomes including postoperative infection and device malfunction.

Results: 63 (20.7%) surgeries resulted in postoperative complications: 38 (12.5%) resulting in device malfunction and 25 (8.20%) resulting in infection. Smoking (odds ratio [OR] = 4.14, P = .00) was associated with overall postoperative complications. Within subgroups, concomitant procedures (OR = 4.77, P = .03) were associated with infection for those undergoing virgin implantation, but not those undergoing revision procedures. Alternatively, diabetes mellitus (DM) (OR = 28.3, P = .02) was associated with postoperative infection for those undergoing revision procedures, but not those undergoing virgin implantation.

Conclusion: The rate of postoperative infection for all patients undergoing IPP was found to be 8.20%, a higher estimate than historically recorded. To varying degrees, smoking, concomitant procedures, and DM were associated with adverse operative outcomes. Subset analyses revealed significant associations between postoperative infections and either concomitant procedures or DM in those undergoing virgin implantations or revision surgeries, respectively. Miller JA, Bennett NE. Comparing Risk Factors for Adverse Outcomes in Virgin Inflatable Penile Prosthesis Implantations and Revisions: A Retrospective Cohort Study. J Sex Med 2020;8:388–395.

Key Words: Prosthesis; Surgical Therapy; Infection; Erectile Dysfunction

INTRODUCTION

Inflatable penile prosthesis (IPP) placement remains a common therapy for erectile dysfunction (ED) when medical therapies are unsuccessful. While IPP placement is typically reserved for refractory cases of ED, patients treated with IPP report higher rates of satisfaction than patients treated with other remedies.1,2 Despite this, adverse outcomes of IPP continue to present a burdensome problem. Postoperative complications for IPP, namely infection and device malfunction, result in harm to the patient, patient dissatisfaction, and costly interventions.3 Of these complications, postoperative infection has gained the most attention.

While historically, the infection rate following virgin IPP placements was reported at 10%,4–12 recent studies place this estimate closer to 0.5–3%.6–12 Much of the success in lowering the rate of postoperative infection is likely due to a combination
of the use of antibiotic-coated prostheses,7–13 “no touch” surgical technique,10 the Mulcahy salvage protocol,14–16 and alcohol-based skin prep regimens.7,19 In addition, this reduction is likely due in part to the identification of at-risk demographics.

Studies examining these demographics have identified those with diabetes mellitus (DM) and undergoing IPP revision to be at a higher risk of infection.4,5,7,8,12 These risk factors remain somewhat controversial as multiple studies disagree regarding the true effect of each risk factor. Regarding the most examined potential risk factor, some studies showed the risk of postoperative infection for those with DM to range up to 18%.4 However, more recent studies have not found a statistically significant relationship between DM and adverse surgical outcomes.5,12,19 Concerning patients undergoing IPP revisions, studies have shown that the rate of infection in this group is 2–3 times greater,5,8 and up to 10 times greater,12 than that following virgin implantations.

Despite the improvement in infection rates and identification of those at risk, knowledge gaps remain in the current research pool. Postoperative infection rates may be underestimated due to the exclusion of high-risk groups from large studies. Many studies exclude patients undergoing revision surgeries.3,6,7,9,20 Even within those studies including this group, many do not discuss patients undergoing revisions following IPP infections.5,10,11,14 and patients requiring multiple revisions over time.5,6 Furthermore, studies have not fully explored whether risk factors are equally predictive for virgin implantations and revisions. In this study, we aim to determine the rates of postoperative complications following IPP implantation and revision for all patients, including patients for whom revisions are performed following infection and patients who have undergone multiple IPP revisions. In addition, we aim to determine the factors associated with postoperative complications for virgin implantations and revisions independently.

**MATERIALS AND METHODS**

An institutional electronic data repository, programmed to identify all patients undergoing IPP procedures, identified the charts of 280 patients undergoing 331 procedures performed at an academic medical center involved in resident teaching between January 2000 and May 2018; these charts were obtained and reviewed retrospectively. Of the 280 patients and 331 surgical encounters examined, 23 patients and 26 surgical encounters were excluded from this study due to lack of either sufficient procedure documentation or follow-up. Of the 305 remaining surgical encounters, 208 involved virgin implantations and 97 involved revision surgeries due to IPP infection, device malfunction, or patient dissatisfaction. For the patients included, the age at implantation ranged between 28 and 91 years, with an average age at implantation of 61 years, and the average follow-up time was 29 months. The demographic characteristics available for the patients included are summarized in Table 1.

Implantations were performed on an outpatient basis by 14 attending surgeons following a standard surgical protocol. Implant models were recorded for all but 30 cases. The implant models used were as follows: AMS 700CX (n = 217), Coloplast Titan (n = 38), AMS Ambicor (n = 15), and AMS Spectra (n = 5). All aforementioned implants used either antibiotic coatings or hydrophilic coatings with antibiotic dips. Preoperative skin preparations were recorded for all but 22 cases. The skin preparations recorded were as follows: Betadine scrub and ChloraPrep (n = 85), Betadine scrub and DuraPrep (n = 56), ChloraPrep alone (n = 43), Betadine alone (n = 35), and other skin preparations used in fewer than 5 individual cases. Of these skin preparations, 242 involved the use of at least 1 alcohol-based solution. In 43 cases, patients underwent concomitant procedures (Table 2). For those undergoing revision surgeries, washout, following the 7-step Mulcahy irrigation and washout protocol17 or the modified Mulcahy washout protocol14,16 was performed in all but 5 cases.

Patient charts were reviewed for postoperative complications. For those with IPPs implanted at other health care facilities prior to revision at the observed institution, previous health records were obtained and reviewed. Each patient’s chart was examined for demographics, DM, hypertension, obesity, coronary artery disease, smoking, Peyronie’s disease, prostate cancer, prior IPP procedures, attending surgeon, implant type, skin prep regimen, procedure duration, and concomitant procedures. Statistical analysis was performed using multiple logistic regression to determine associations between adverse postoperative outcomes and the variables mentioned earlier. Collinearity between these variables was ruled out using the variance inflation factor (VIF), with a VIF>5 suggesting significant interaction between variables; variables with VIF>5 were removed from the tests in which collinearity was demonstrated. Subset analyses were performed to reveal associations between the aforementioned variables and postoperative complications following virgin implantations and revision surgeries separately. Patients with missing data regarding the presence or absence of these variables were excluded from those respective analyses.

For all statistical analyses, P < .05 was considered statistically significant. Multiple logistic regressions involving all cases were found to have a power of 1.00 and 0.99 for large ($f^2 = 0.35$) and medium ($f^2 = 0.15$) effect sizes, respectively. For patients undergoing virgin implantation, regressions were found to have a power of 1.00 and 0.98 for large and medium effect sizes, respectively. For patients undergoing revision surgeries, regressions were found to have a power of 0.98 for large effect sizes; in this subset, analyses were underpowered in relation to medium effect sizes due to sample size.

**RESULTS**

The duration of each procedure ranged between 1 and 5 hours, with an average duration of 2.16 hours, and in cases
involving revisions or concomitant procedures taking on average 25–30 minutes longer, respectively ($P = .00$). Complications were noted in 63 of the 305 surgeries (20.7%). Of these complications, 25 were infections (8.20%) and 38 were device malfunctions (12.5%). The nature of device malfunctions varied between cases and included pump malfunctions ($n = 17$), cylinder erosions ($n = 12$), reservoir leakage ($n = 3$), and device malfunctions not otherwise specified ($n = 6$). Complications occurring during concomitant procedures are described below (Table 3). Across all cohorts, outcomes were not significantly associated with self-reported race/ethnicity, attending surgeon, or implant type ($P > .05$). Of the variables analyzed for the overall cohort (Table 4), smoking was associated with overall complications (odds ratio [OR] = 4.14, $P = .00$) and device malfunction (OR = 3.14, $P = .04$).

For those undergoing virgin implantation, complications were noted following 36 implantations (17.3%), including 14 infections (6.73%) and 22 device malfunctions (10.6%). Within this cohort (Table 5), smoking was associated with overall complications (OR = 4.12, $P = .02$), and concomitant procedures were associated with infection (OR = 4.77, $P = .03$). For those undergoing revision surgeries, complications were noted following 27 implantations (27.8%), including 10 infections (10.3%) and 17 device malfunctions (17.5%). Within this sample (Table 6), smoking was associated with overall complications (OR = 7.85, $P = .02$), and DM was associated with infection (OR = 28.3, $P = .02$).

### Table 1. Demographic characteristics of the study samples

| Characteristic                  | Percentage of all cases, % (n = 305) | Percentage of virgin implantations, % (n = 208) | Percentage of revisions, % (n = 97) | $P$ value |
|--------------------------------|--------------------------------------|-----------------------------------------------|-----------------------------------|-----------|
| Age (in years)                 |                                      |                                               |                                   | .09       |
| 20–29                          | 0.33 (1)                             | 0.00 (0)                                      | 1.03 (1)                          |           |
| 30–39                          | 4.59 (14)                            | 3.85 (8)                                      | 6.19 (6)                          |           |
| 40–49                          | 9.84 (30)                            | 6.73 (14)                                     | 16.5 (16)                         |           |
| 50–59                          | 26.6 (81)                            | 29.3 (61)                                     | 20.6 (20)                         |           |
| 60–69                          | 37.0 (113)                           | 40.4 (84)                                     | 29.9 (29)                         |           |
| 70–79                          | 18.7 (57)                            | 17.3 (36)                                     | 21.6 (21)                         |           |
| 80–89                          | 2.62 (8)                             | 2.40 (5)                                      | 3.09 (3)                          |           |
| 90–99                          | 0.33 (1)                             | 0.00 (0)                                      | 1.03 (1)                          |           |
| Race/ethnicity                 |                                      |                                               |                                   | .24       |
| White or Caucasian             | 58.0 (177)                           | 56.3 (117)                                    | 61.9 (60)                         |           |
| Black or African American      | 25.6 (78)                            | 25.0 (52)                                     | 26.8 (26)                         |           |
| Hispanic or Latino             | 1.31 (4)                             | 0.96 (2)                                      | 2.06 (2)                          |           |
| Other or unreported            | 15.1 (46)                            | 17.8 (37)                                     | 9.28 (9)                          |           |
| Comorbidities                  |                                      |                                               |                                   |           |
| Diabetes mellitus              | 34.8 (106)                           | 31.2 (65)                                     | 42.3 (41)                         | .06       |
| Hypertension                   | 43.0 (131)                           | 42.3 (88)                                     | 44.3 (43)                         | .77       |
| Obesity                        | 29.5 (90)                            | 30.3 (63)                                     | 27.8 (27)                         | .64       |
| CAD                            | 19.3 (59)                            | 17.3 (36)                                     | 23.7 (23)                         | .19       |
| Peyronie’s disease             | 16.1 (49)                            | 15.9 (33)                                     | 16.5 (16)                         | .89       |
| Prostate cancer                | 39.3 (120)                           | 47.1 (98)                                     | 22.7 (22)                         | .00*      |
| Smoking                        | 9.51 (29)                            | 8.17 (17)                                     | 12.4 (12)                         | .25       |
| Concomitant procedures         | 14.1 (43)                            | 14.4 (30)                                     | 13.4 (13)                         | .81       |

$P$ values compare the demographic characteristics of those in the virgin implantation group and the revision group.

CAD = coronary artery disease.

*P value ≤ .05.

### Table 2. Concomitant procedures performed at the time of inflatable penile prosthesis insertion or revision

| Concomitant procedure          | Frequency |
|--------------------------------|-----------|
| Corporoplasty                  | 16        |
| AUS insertion                  | 7         |
| AUS insertion with penile plication | 4    |
| Vasectomy                      | 4         |
| Frenullectomy                  | 2         |
| Injection of bladder Botox     | 1         |
| Circumcision                   | 1         |
| Scrotal abscess drainage       | 1         |
| Inguinal herniorrhaphy         | 1         |
| Hydrocelecomy                  | 1         |
| Repair of urethral perforation | 1         |
| Scrotoplasty                   | 1         |
| Penile skin grafting           | 1         |
| Spermatocelectomy              | 1         |
| UroLift implantation           | 1         |

N = 43

AUS = artificial urinary sphincter.
DISCUSSION

Recent studies have found the rate of postoperative infection following IPP implantation to be between 0.5% and 3%.6 However, many of these recent studies exclude at-risk demographics, such as those with a history of prior IPP implantation,3,6,7,9,20 IPP infection,5,10,11,14 and successive revisions.5,8 After including these at-risk demographics, our study determined the rate of postoperative infection to be 8.20%, a rate higher than that quoted in recent studies.

Prior studies describe contradicting evidence regarding DM as a predictive factor for postoperative infection. Wilson and Delk noted this effect in their 1995 study, in which patients with DM experienced a rate of infection that was 10% greater than those without DM.4 However, in Mulcahy and Carson’s 2011 study, this rate was only 0.30% greater than that for patients without DM. Other studies, such as the multicenter study of Henry et al in 2012 and the study by Lotan et al in 2003 have been unable to reproduce a significant association.5,19 The aforementioned data may offer an explanation behind the varying effect of DM on postoperative outcomes. In the overall cohort, the odds that those with DM experienced postoperative infections was increased by nearly 3.5 times, although this effect was not significant, supporting the Henry et al and Lotan et al studies. However, when data were split between the 2 subgroups, a significant association between DM and infection was established for those undergoing revision, supporting the Wilson and Delk study. These results, and the contradicting evidence establishing DM as a predictor of infection, may be explained by the interaction between DM and a history of prior IPP implantation.

This study may also provide new information regarding the associations between other medical comorbidities and postoperative outcomes. The effects of smoking on postoperative outcomes have been extensively documented in the literature. In their large 2012 meta-analysis, Sørensen demonstrated ORs of 2.27 for wound complications and 1.79 for postoperative superficial site infections in those who smoked within 4 weeks of their procedure.21 The effect that smoking plays on outcomes following the placement of genitourinary prostheses was further described by Sadeghi-Nejad. As described in his study, patients with comorbidities that cause local inflammation and/or negatively affect peripheral vascular supply, including smoking, experienced higher rates of device malfunctions, specifically erosion and pump migration.22 Mirroring the findings from these studies, the OR of overall complications for active smokers was significantly increased by approximately 4 times. Of note, the majority of device malfunctions noted within this cohort, namely erosion and pump migration, match those described by

Table 3. Complications following concomitant procedures

| Complications                        | Frequency |
|--------------------------------------|-----------|
| Infection                            |           |
| Corporoplasty                        | 2         |
| AUS insertion with penile plication  | 1         |
| Scrotal abscess drainage             | 1         |
| Frenulectomy                         | 1         |
| Hydrocelectomy                       | 1         |
| Repair of urethral perforation       | 1         |
| Device malfunction                   |           |
| Corporoplasty                        | 2         |
| AUS insertion with penile plication  | 1         |
| Vasectomy                            | 1         |
| Circumcision                         | 1         |
| Inguinal herniorrhaphy               | 1         |

N = 13.
AUS = artificial urinary sphincter.

Table 4. ORs for adverse postoperative outcomes by risk factor

| Complications, OR (P value) | Infection, OR (P value) | Device malfunction, OR (P value) |
|-----------------------------|------------------------|---------------------------------|
| Peyronie’s disease (n = 49) | 0.69 (.45)             | 0.56 (.41)                      | 0.81 (.71)                      |
| Prostate cancer (n = 120)   | 0.67 (.30)             | 1.11 (.86)                      | 0.60 (.29)                      |
| Diabetes mellitus (n = 106) | 1.30 (.50)             | 2.87 (.06)                      | 0.69 (.46)                      |
| Hypertension (n = 131)      | 0.88 (.74)             | 0.97 (.95)                      | 0.88 (.80)                      |
| Obesity (n = 90)            | 0.87 (.73)             | 0.77 (.65)                      | 1.03 (.95)                      |
| CAD (n = 59)                | 1.57 (.33)             | 2.11 (.22)                      | 1.41 (.57)                      |
| Smoking (n = 29)            | 4.14 (.00)             | 2.91 (.08)                      | 3.14 (.04)*                     |
| Concomitant procedure (n = 43)| 2.12 (.11)         | 3.14 (.05)                      | 1.51 (.49)                      |
| Age                         | 1.00 (.95)             | 0.98 (.42)                      | 1.01 (.80)                      |
| Year of procedure           | 0.93 (.09)             | 0.97 (.60)                      | 0.92 (.10)                      |
| Number of prior IPP surgeries| 1.19 (.32)            | 1.15 (.59)                      | 1.17 (.46)                      |
| Procedure duration          | 0.76 (.32)             | 0.66 (.29)                      | 0.81 (.55)                      |
| Alcohol-based skin prep (n = 242)| 0.81 (.65)     | 1.62 (.55)                      | 0.58 (.27)                      |

N = 305.
CAD = coronary artery disease; IPP = inflatable penile prosthesis; OR = odds ratio.
*P value ≤ .05.
†P value ≤ .01.
Sadeghi-Nejad. Other comorbidities, namely Peyronie’s disease, prostate cancer, hypertension, obesity, and coronary artery disease, were revealed to be poor predictors of postoperative complications. Similarly, no significant associations were demonstrated between postoperative outcomes and demographic factors, such as age and self-reported race/ethnicity.

Prior studies have provided varied evidence regarding the rate of postoperative complications for those undergoing IPP revision. While all but one study reviewed revealed that those undergoing revision experienced greater rates of complications, the reported complication rates for these patients have varied. While some studies quote the infection rate for these patients to be as high as 10–18%, other studies report that, with proper device washout and the use of other infection limiting techniques, this rate may be as low as 3–4%. While patients undergoing revision procedures (10.3%) in this study experienced higher rates of postoperative infection than those undergoing virgin implantation (6.73%), a statistically significant association was not established. The disparity between the aforementioned data and the results of the described previous studies may be due to a number of causes. For one, there may be a non-linear association, which may not be detectable through linear regression. Specifically, the risk of complication may not increase with successive revisions, but rather remain constant following the first revision procedure. In addition, it may be that those who require multiple revisions are more likely to experience other risk factors, including longer procedure durations and higher rates of smoking and DM. As such, it may be that, when controlling for other variables, the association between past IPP procedures and complications becomes insignificant. Lastly, this

### Table 5. ORs for adverse postoperative outcomes by risk factor for virgin implantations

| Risk Factor                              | Complications, OR (P value) | Infection, OR (P value) | Device malfunction, OR (P value) |
|------------------------------------------|-----------------------------|-------------------------|----------------------------------|
| Peyronie’s disease (n = 33)              | 0.96 (.95)                  | 0.50 (.56)              | 1.19 (.80)                       |
| Prostate cancer (n = 98)                 | 0.49 (.13)                  | 1.19 (.81)              | 0.35 (.09)                       |
| Diabetes mellitus (n = 65)               | 0.84 (.74)                  | 0.96 (.96)              | 0.90 (.87)                       |
| Hypertension (n = 88)                    | 0.90 (.82)                  | 1.50 (.57)              | 0.69 (.54)                       |
| Obesity (n = 63)                         | 0.80 (.65)                  | 0.98 (.98)              | 0.77 (.67)                       |
| CAD (n = 36)                             | 1.54 (.46)                  | 3.16 (.13)              | 1.03 (.97)                       |
| Smoking (n = 17)                         | 4.12 (.02)*                 | 3.18 (.21)              | 2.98 (.13)                       |
| Concomitant procedure (n = 30)           | 2.85 (.07)                  | 4.77 (.03)*             | 1.76 (.46)                       |
| Age                                      | 1.02 (.35)                  | 0.99 (.76)              | 1.02 (.42)                       |
| Year of procedure                        | 0.96 (.47)                  | 1.05 (.57)              | 0.91 (.15)                       |
| Procedure duration                       | 0.74 (.46)                  | 0.75 (.64)              | 0.63 (.40)                       |
| Alcohol-based skin prep (n = 168)        | 0.67 (.48)                  | 2.30 (.47)              | 0.43 (.19)                       |

N = 208.
CAD = coronary artery disease; OR = odds ratio.
*P value ≤ .05.

### Table 6. Relative risk for adverse postoperative outcomes by risk factor for revision surgeries

| Risk Factor                              | Complications, OR (P value) | Infection, OR (P value) | Device malfunction, OR (P value) |
|------------------------------------------|-----------------------------|-------------------------|----------------------------------|
| Peyronie’s disease (n = 16)              | 0.38 (.32)                  | 0.34 (.44)              | 0.32 (.36)                       |
| Prostate cancer (n = 22)                 | 1.02 (.98)                  | NA                      | 4.38 (.16)                       |
| Diabetes mellitus (n = 41)               | 2.56 (.20)                  | 28.3 (.02)*             | 0.19 (.14)                       |
| Hypertension (n = 43)                    | 0.94 (.95)                  | 0.64 (.72)              | 3.43 (.36)                       |
| Obesity (n = 27)                         | 1.19 (.81)                  | 1.42 (.77)              | 2.40 (.41)                       |
| CAD (n = 23)                             | 1.94 (.43)                  | 0.59 (.67)              | 7.15 (.12)                       |
| Smoking (n = 12)                         | 7.85 (.02)*                 | 7.70 (.14)              | 10.3 (.06)                       |
| Concomitant procedure (n = 13)           | 0.91 (.92)                  | 0.29 (.50)              | 1.12 (.92)                       |
| Age                                      | 0.97 (.37)                  | 0.97 (.54)              | 0.93 (.25)                       |
| Year of procedure                        | 0.87 (.11)                  | 0.83 (.21)              | 0.83 (.17)                       |
| Number of prior IPP surgeries            | 1.35 (.31)                  | 1.01 (.99)              | 1.54 (.18)                       |
| Procedure duration                       | 0.78 (.56)                  | 0.37 (.22)              | 0.98 (.97)                       |
| Alcohol-based skin prep (n = 74)         | 0.88 (.88)                  | 0.76 (.84)              | 0.76 (.80)                       |

N = 97.
CAD = coronary artery disease; IPP = inflatable penile prosthesis; NA = omitted due to collinearity with other variables; OR = odds ratio.
*P value ≤ .05.
Given these and other similar results, it is the recommendation of the International Consultation for Sexual Medicine that alcohol-based skin prep regimens be used prior to prosthesis placement. As such, it is strange that no significant associations were found between the use of alcohol-based skin prep regimens and postoperative infection. Given the prevalence with which alcohol-based skin prep regimens are now used, the number of cases for which alcohol-based regimens were not used was low (n = 41). As such, it is likely that this sample was too small for the findings of these previous studies to be confirmed.

Multiple limitations exist within this study. Many patients were lost to follow-up and thus excluded from the final analyses. Assuming that many patients who experience postoperative complications will need to return for continued care, especially in the case of postoperative infection, it is possible that patients lost to follow-up did not go on to experience adverse postoperative outcomes. While the exclusion of these patients allowed for a more accurate analysis to take place, it is possible that the data overestimate the rate of complications as a result of this exclusion. In addition, by organizing this study’s data by surgical encounter, we were able to better examine the risk factors relevant to successive IPP revisions. However, this decision creates a risk for potential confounding effects to influence the results, as uncounted risk factors may have been included multiple times for patients undergoing successive revisions.

Given the limits imposed by the data available, the effect of certain variables of interest could not be examined, including preoperative glucose levels, preoperative body mass index, prior steroid use, spinal cord injury, and sexual activity following implantation or revision. An additional missing variable that could potentially have a large effect on the data was antibiotic prophylaxis regimen. While the majority of patients included were given preoperative and intraoperative prophylactic antibiotics, the manner in which these regimens were recorded was not consistent. As such, a reliable analysis examining the relative success of these regimens in preventing postoperative infections could not be performed. As variations in these regimens may have had a direct impact on the rates of postoperative infection, the lack of such an analysis represents a significant limitation of the study.

Given that the study performed was a retrospective cohort study, and the complication status of each patient was known prior to examining patient charts, there is potential for confirmation bias to have affected the results. This limitation was addressed by recording and analyzing only objective variables, namely laboratory data and established medical diagnoses recorded prior to surgery.

Lastly, it is possible that the sample size was too small to detect significant associations for each of the variables examined. This limitation is especially relevant for the analyses regarding prior IPP surgeries and skin prep regimens; this could potentially explain the lack of significant associations regarding these variables, though these associations have been established in the literature. In addition, this limitation imposed barriers to testing uncommon risk factors, including surgical alteration for Peyronie’s disease and lack of washout during revision. While there may be significant associations linking these factors to postoperative infection, it was not feasible to analyze these variables.

Future research appears necessary to fully understand the factors associated with complications following IPP procedures.
More research is needed to investigate the results described for the first time in this study, including the association between concomitant procedures and infection. In addition, given the extensive documentation of certain variables as predictive of complications, future research should be dedicated toward developing a clinical risk score to predict complications prior to IPP procedures. With a clinical risk score, physicians may more effectively counsel patients seeking treatment for ED and prevent the negative effects encountered with postoperative complications. Lastly, future studies should further investigate if certain risk factors are more pronounced following virgin implantation or revision procedures separately, such as the effects described earlier with DM and concomitant procedures.

CONCLUSION

The rates of postoperative complications in patients undergoing IPP implantation may be underestimated due to the exclusion of high-risk patients. Our examination of the outcomes for all patients undergoing IPP procedures over 18 years found the rate of postoperative infection to be 8.20%. An investigation of potential risk factors found smoking, DM, and concomitant procedures to be associated with varying rates of complications. The differences in risk factors for patients undergoing virgin implantation and revision were examined, revealing DM to be associated with infection for those undergoing revision, and concomitant procedures to be associated with infection for those undergoing virgin implantation.

Corresponding Author: Nelson E. Bennett, Jr., MD, 675 N. St Clair St. Ste 20-150, Chicago, IL 60611, USA. Tel: (312) 695-8146; E-mail: Nelson.Bennett@nm.org

Conflict of Interest: The authors report no conflicts of interest.

Funding: None.

STATEMENT OF AUTHORSHIP

Category 1
(a) Conception and Design
Nelson E. Bennett, Jr.; Jake A. Miller
(b) Acquisition of Data
Jake A. Miller
(c) Analysis and Interpretation of Data
Jake A. Miller

Category 2
(a) Drafting the Article
Jake A. Miller
(b) Revising It for Intellectual Content
Jake A. Miller; Nelson E. Bennett, Jr.

Category 3
(a) Final Approval of the Completed Article
Jake A. Miller; Nelson E. Bennett, Jr.

REFERENCES
1. Rajpurkar A, Dhabuwala CB. Comparison of satisfaction rates and erectile function in patients treated with Sildenafil, Intracavernous Prostaglandin E1 and penile implant surgery for erectile dysfunction in Urology Practice. J Urol 2003;170:159-163.
2. Govier FE, Gibbons RP, Correa RJ, et al. Mechanical Reliability, surgical complications, and patient and partner satisfaction of the modern three-piece inflatable penile prosthesis. Urology 1998;52:282-286.
3. Carson CC. Efficacy of antibiotic Impregnation of inflatable penile prostheses in Decreasing infection in Original implants. J Urol 2004;171:1611-1614.
4. Wilson SK, Delk JR. Inflatable penile implant infection: predisposing factors and treatment Suggestions. J Urol 1995;153:659-661.
5. Lotan Y, Roehrborn CG, McConnell JD, et al. Factors influencing the outcomes of penile prosthesis surgery at a teaching institution. Urology 2003;62:918-921.
6. Carson CC, Mulcahy JJ, Harsch MR. Long-term infection outcomes after Original antibiotic Impregnated inflatable penile prosthesis implants: up to 7.7 Years of follow-up. J Urol 2011;185:614-618.
7. Mulcahy JJ, Carson CC. Long-term infection rates in diabetic patients implanted with antibiotic-Impregnated versus Non-impregnated inflatable penile prostheses: 7-year outcomes. Eur Urol 2011;60:167-172.
8. Wilson SK, Zumbe J, Henry GD, et al. Infection reduction using antibiotic-coated inflatable penile prosthesis. Urology 2007;70:337-340.
9. Mandava SH, Serefoglu EC, Freier MT, et al. Infection Retardant coated inflatable penile prostheses Decrease the Incidence of infection: a systematic review and meta-analysis. J Urol 2012;188:1855-1860.
10. Eid JF, Wilson SK, Cleves M, et al. Coated implants and ‘No touch’ surgical technique Decreases risk of infection in inflatable penile prosthesis implantation to 0.46%. Urology 2012;79:1310-1316.
11. Montague DK. Does Antiseptic washout Reduce penile prosthesis infection following revision Surgery?(clinical report). Nat Clin Pract Urol 2005;2:222-223.
12. Elmussareh M, Goddard JC, Summerton DJ, et al. Minimising the risk of device infection in penile prosthetic surgery: a UK Perspective. J Clin Urol 2013;6;280-288.
13. Henry G, Wilson SK, Carson CC, et al. Infection Retardant coated versus Non-coated penile prosthesis Cultures during revision surgery: a multicenter study. J Urol 2013;189:E685.
14. Henry G, Wilson SK, Carson CC, et al. Revision washout Decreases penile prosthesis infection in revision surgery: a multicenter study. J Urol 2005;173:89-92.
15. Brant MD, Ludlow JK, Mulcahy JJ. The prosthesis salvage operation: Immediate Replacement of the infected penile prosthesis. J Urol 1996;155:155-157.
16. Hinds PR, Wilson SK, Sadeghi-Nejad H. Dilemmas of inflatable penile prosthesis revision surgery: what Practices Achieve the
best outcomes and the lowest infection rates? (CME). J Sex. Med 2012;9:2483-2492.

17. Darouiche RO, Wall MJ Jr, Itani KM, et al. Chlorhexidine-alcohol versus povidone-iodine for surgical-site antisepsis. N Engl J Med 2010;362:18-26.

18. Yeung LL, Grewal S, Bullock A, et al. A comparison of chlorhexidine-alcohol versus povidone-iodine for eliminating skin flora before genitourinary prosthetic surgery: a randomized controlled trial. J Urol 2013;189:136-140.

19. Henry G, Wilson SK, Carson CC, et al. An outcomes analysis of over 200 revision surgeries for penile prosthesis implantation: a multicenter study. J Sex Med 2012;9:309-315.

20. Wilson SK, Delk JR, Salem EA, et al. “Long-Term Survival of inflatable penile prostheses: single surgical group experience with 2,384 first-time implants Spanning two Decades. J Sex. Med 2007;4:1074-1079.

21. Sørensen LT. Wound healing and infection in surgery. The clinical impact of smoking and smoking cessation: a systematic review and meta-analysis. Arch Surg 2012;147:373-383.

22. Sadeghi-Nejad H. Penile prosthesis surgery: a review of prosthetic devices and associated complications. J Sex Med 2007;4:296-309.

23. Segal RL, Cabrini MR, Harris ED, et al. Combined inflatable penile prosthesis-artificial urinary sphincter implantation: no increased risk of adverse events compared to single or staged device implantation. J Urol 2013;190:2183-2188.

24. Gorbatiy V, Westney OL, Romero CA, et al. Outcomes of simultaneous placement of an inflatable penile prosthesis and a male urethral sling through a single perineal incision. J Sex Med 2010;7:832-838.

25. Thornalla JV, Thompson ST, Rowland RG, et al. Infectious complications of penile prosthetic implants. J Urol 1987;138:65-67.

26. Weinberg AC, Pagano MJ, Deibert CM, et al. Sub-coronal inflatable penile prosthesis placement with modified No-touch technique: a step-by-step Approach with outcomes. J Sex Med 2016;13:270-276.

27. Raheem O, Khalil M, Acharya M, et al. Perioperative morbidity of penile prosthesis placement with concurrent surgery. A National report.” J Urol 2020;203:e577.

28. Levine LA, Becher EF, Bella AJ, et al. Penile prosthesis surgery: current recommendations from the International Consultation on sexual medicine. J Sex Med 2016;13:489-518.